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Abstract 
Background: Betatrophin has been suggested as an inducer of β‑cell proliferation in mice in addition to its function 
in regulating triglyceride. Recent data showed that betatrophin was increased in Type 2 Diabetes (T2D), however, its 
ability to induce insulin production has been questioned. We hypothesized that the increased betatrophin in T2D is 
not affecting insulin production from β‑cells. To test this hypothesis, we investigated the association between betatro‑
phin and C‑peptide level in humans, which acts as a measure of endogenous insulin production from β‑cells.
Methods: This study was designed to examine the association between plasma betatrophin level and C‑peptide in 
749 T2D and non‑diabetics.
Results: Betatrophin and C‑peptide levels were higher in T2D subjects compared with non‑diabetics subjects. 
Betatrophin showed strong correlation with C‑peptide in non‑diabetics subjects (r = 0.28, p = < 0.0001). No associa‑
tion between betatrophin and C‑peptide were observed in T2D subjects (r = 0.07, p = 0.3366). Dividing obese and 
non‑obese subjects into tertiles according to betatrophin level showed significantly higher C‑peptide levels at higher 
tertiles of betatrophin in obese non‑diabetics subjects P‑trend = 0.0046. On the other hand, C‑peptide level was 
significantly higher in subject with higher betatrophin level in non‑diabetics subjects across all age groups but not 
in T2D subjects. Multiple logistic regression models adjusted for age, BMI, gender, ethnicity as well as C‑peptide level 
showed that subjects in the highest tertiles of betatrophin had higher odds of having T2D [odd ratio (OR) = 7.3, 95 % 
confidence interval (CI) 4.0–13.3].
Conclusion: Increased betatrophin level in obese subjects is correlated with an increase in C‑peptide level; which is 
possibly caused by the increased insulin resistance. On the other hand, no correlation is observed between increased 
betatrophin level and C‑peptide in T2D subjects. In conclusion, the increased betatrophin in T2D subject does not 
cause any increase in insulin production as indicated by C‑peptide level.
© 2015 Abu‑Farha et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Regeneration of insulin producing β-cells in diabetic 
patients has been cherished as the ultimate treatment 
for type 1 diabetes (T1D) and T2D [1–4]. It is well 
documented that β-cell replication slows down dramati-
cally under physiological conditions in adult humans and 
rodents [5, 6]. Enhanced β-cell proliferation occurs natu-
rally during pregnancy [5, 7] as well as obesity induced 
states of insulin resistance [8, 9].The recent discovery of 
betatrophin as a potential inducer of β-cell proliferation 
in mice in response to insulin resistance has revived the 
hope for achieving this goal [10, 11]. Betatrophin was ini-
tially identified as an ANGPTL protein family member 
and named ANGPTL8 due to its high similarity to angi-
opoetin like proteins [12, 13]. Many studies supported 
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this role of betatrophin in lipid metabolism and adipo-
cytes differentiation [12–18]. In an exciting twist, Yi et al. 
has shown that betatrophin, a liver and adipose tissue 
derived hormone, was able to induce β-cell prolifera-
tion in insulin resistant mouse model [11]. This finding 
caused huge excitement in the field of beta-cell regen-
eration as a potential alternative treatment for diabetes 
[10, 19]. Nonetheless, Jiao et al. demonstrated that beta-
trophin was able to cause strong induction of the β-cells 
proliferation in mice but not humans [20]. The authors 
questioned the ability of betatrophin to induce β-cell 
proliferation but highlighted a major caveat in their data 
which was the ability of the mouse betatrophin to act on 
the human receptor [20]. Recent reports have challenged 
the ability of betatrophin to induce β-cell proliferation 
[21, 22]. Gusarova et al. showed that β-cells lacking both 
copies of betatrophin were producing insulin normally 
under insulin resistance conditions [22].
A number of studies showed that betatrophin level was 
increased in type 1 [23], T2D [23–28] and gestational dia-
betes [29]. Using a large sample cohort we have recently 
showed that betatrophin level was increased in T2D, 
however, it was not affecting fasting blood glucose (FBG) 
or insulin production in T2D subjects [30]. As a result, a 
major question has been raised regarding the function of 
betatrophin in T2D and its ability to induce β-cell pro-
liferation as well as its physiological role in humans [19, 
20, 22, 31]. To answer this question, we designed a study 
to look at the association between betatrophin level and 
C-peptide in diabetic and non-diabetic subjects to under-
stand the effect of betatrophin on the secretion of insulin. 
C-peptide is a cleavage product of proinsulin that is pro-
duced by the pancreatic β-cells at an equimolar amounts 
to insulin [32]. It is commonly used to assess β-cell func-
tion due to its longer half life and its ability to indicate 
endogenous insulin production in patients taking insulin 
treatments [32].
Research design and methods
Study participants and anthropometric and physical 
measurements
This is a study was performed on 749 adult (>18  years 
old) South Asians (Indians and Pakistanis) and Arabs liv-
ing in Kuwait. The study was designed as cross-sectional. 
Samples have been randomly collected from multi-
ethnic subjects living in Kuwait as described previously 
[33, 34]. Samples were continuously collected. Briefly, 
study participants suffering from any kind of infection as 
well as subjects younger than 18 and older than 65 were 
excluded. The non-diabetic subjects were then selected 
as subjects without disease and not taking any medica-
tions. Most subjects were taking oral hypoglycaemic 
agents alone (metformin, sulfonylurea and dipeptidyl 
peptidase-4 inhibitors), insulin alone or insulin with 
oral hypoglycaemic agents. A small number of subjects 
were using exercise and diet to control their diabetes. 
In addition, diabetic patients were taking lipid lowering, 
anti-Asthma and anti-hypertensive drugs. Subjects with 
cardiovascular diseases were excluded from the study. No 
treatment was received before sampling. Even though the 
selected participants had similar population characteris-
tics as the total study population in terms of age, gender, 
FBG, body mass index (BMI), blood pressure (BP) and 
lipid profile, the T2D and the non-diabetic group were 
not exactly matched posing as one of the limitations of 
this study. The study conformed to the principles out-
lined in the Declaration of Helsinki and in accordance 
with the approved guidelines. The study was approved by 
the Ethical Review Committee at Dasman Diabetes Insti-
tute (DDI). An informed written consent was obtained 
from all the participants before their enrolment in the 
study.
Physical and anthropometric measurements included 
body weight, height, waist circumference (WC) were 
measured as described previously [33, 34]. Height and 
weight were measured, with participants wearing light 
indoor clothing and barefooted, using calibrated portable 
electronic weighing scales and portable inflexible height 
measuring bars. WC was measured using constant ten-
sion tape at the end of a normal exhalation, with arms 
relaxed at the sides, at the highest point of the iliac crest 
and at the mid-axillary line. BMI was calculated using 
the standard BMI formula: body weight (in kilograms) 
divided by height (in meters squared).
Laboratory measurements
Blood samples were obtained after fasting overnight 
for at least 10  h and analyzed for FBG, HbA1c, fast-
ing insulin, and lipid profiles that included triglyceride 
(TG), Total cholesterol (TC), low density lipoprotein 
(LDL) and high density lipoprotein (HDL). Glucose and 
lipid profiles were measured on the Siemens Dimen-
sion RXL chemistry analyzer (Diamond Diagnostics, 
Holliston, MA, USA). HbA1c was determined using the 
VariantTM device (BioRad, Hercules, CA, USA). All 
laboratory tests were performed by certified technicians 
at the clinical laboratories of DDI using the Ministry of 
Health approved methods and quality standards. Insulin 
resistance was calculated using the homeostatic model 
assessment-insulin resistance (HOMA-IR) formula: FBG 
(mmol/l) × fasting insulin (mU/l)/22.5.
Diabetes diagnosis and guidelines
The current recommendations and updated guidelines 
for the definition, diagnosis and classification of T2D, 
published by the International Diabetes Federation (IDF), 
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have been used as described previously [35]. Diabetes 
was defined by fasting plasma glucose ≥7 mmol/l, under 
treatment, or self-reporting of previously diagnosed T2D 
[35]. Impaired fasting glucose (IFG) was defined by fast-
ing blood glucose values ≥5.6 and <7 mmol/l.
ELISA betatrophin and C‑peptide level
To measure metabolic markers, blood was drawn into 
EDTA tubes. Plasma was obtained after centrifugation, 
aliquoted and then stored at −80 °C. Betatrophin concen-
tration was determined using ELISA (Wuhan EIAAB) as 
reported previously [24, 36, 37]. The assay showed linear-
ity at dilutions ranging from 1:10 to 1:40. No significant 
cross reactivity with other proteins has been observed. 
Intra-assay coefficients of variation were 1.2–3.8 %, while 
the inter-assay coefficients of variation were 6.8–10.2 %. 
C-peptide was measured using Mercodia Ultrasensi-
tive C-peptide ELISA according to the manufacturer’s 
instructions (Mercodia, Uppsala, Sweden). Inter- and 
intra-assay coefficient of variation was <5 %.
Statistical analysis
Normality tests were run to assess data distribution. Com-
parisons between subjects with T2D and without T2D were 
made by Student’s t test or Wilcoxon test for non-paramet-
ric analyses in variables with non-normal distribution. To 
assess the difference in categorical variables between sub-
jects with and without T2D, a Chi Squared test was used. 
Spearman’s correlation coefficients were estimated to deter-
mine associations between betatrophin and anthropometric 
measurements and biochemical variables. Subjects were 
classified into tertiles based on their circulating betatrophin 
levels in the overall population. Betatrophin tertile values 
for non-obese (BMI < 30) non-diabetics and T2D subjects 
are T1: ≤1162.5  pg/mL, T2: 1162.5  ≤  1881.9  pg/mL, 
T3: > 1881.9 pg/mL). Betatrophin tertile values for the obese 
group are T1: ≤ 1273.4 pg/mL, T2: 1273.4 ≤ 1881.9 pg/mL, 
T3:  >  1881.9  pg/mL. Betatrophin tertile values in subjects 
less than 40  years old stratified according to betatrophin 
level in non-diabetics and T2D subjects are T1: ≤ 567.6 pg/
mL, T2: 567.6  ≤  763.5  pg/mL, T3:  >  763.5  pg/mL). B: 
Betatrophin tertiles in non-diabetics and T2D subjects 
between 40 and 50  years old are T1: ≤  743.2  pg/mL, T2: 
743.2  ≤  1070.7  pg/mL, T3:  >  1070.7  pg/mL). Betatro-
phin tertiles in non-diabetics and T2D subjects older than 
50 years old are T1: ≤ 957.7 pg/mL, T2: 957.7 ≤ 1406.3 pg/
mL, T3: > 1406.3 pg/mL).
A multivariable logistic regression analysis was per-
formed to estimate odds ratios (ORs) adjusted for covari-
ates and to assess the predictive effect of betatrophin 
on risk for T2D. All data are reported as Mean ± stand-
ard deviation (SD) and range, unless stated otherwise. 
Research Electronic Data Capture (REDCap) was used 
for data collections and data management. All statistical 
assessments were two-sided and considered to be signifi-
cant when P-value  <  0.05. All analyses were performed 
using SAS (version 9.2; SAS Institute, Cary, NC).
Results
The clinical characteristics of the study population for 
both T2D and non-diabetics subjects are shown in Table 1. 
Our sample cohort was made of 749 subjects, 535 of which 
were non-diabetics and 214 were T2D. The average age of 
participants was 41.3 ± 10.1 years for non-diabetics sub-
jects and 50.5 ± 9.8 years for T2D subjects. T2D subjects 
had higher BMI, waist/hip ratio, systolic BP, diastolic BP, 
FBG, HBA1C, insulin, HOMA-IR, TG, HDL (p  <  0.05). 
TC did not show any significant changes between the two 
groups while LDL level was lower in T2D subjects. Beta-
trophin was higher in subjects with T2D relative to non-
diabetics subjects [1710.1 (197.4–10972.1] pg/mL vs. 720.3 
(59.5–9345.1) pg/mL) respectively. C-peptide was also 
higher in T2D subjects compared to non-diabetics sub-
jects (744.1 ± 419.0 vs. 606.2 ± 300.1 pmol/L).
Partial Spearman correlation coefficients were adjusted 
for age, gender, and ethnicity. Spearman’s correlation 
Table 1 Clinical and biochemical profiles for non-diabetics 
and T2D subjects
Results are reported as Mean ± SD except for non‑normally distributed 
betatrophin that are presented as Median (range). Diabetes: fasting plasma 
glucose ≥ 7 mmol/l, under treatment, or self‑reported of previously diagnosed 
T2D
Variables Normal (n = 535) T2D (n = 214) P value
Age (years) 41.3 ± 10.1 50.5 ± 9.8 <0.0001
Ethnicity
 Arab 285 (53.3 %) 110 (51.4 %)
 South Asian 250 (46.7 %) 104 (49.6 %)
BMI (kg/m2) 29.36 ± 6.23 30.72 ± 5.59 0.0039
Waist/hip ratio 0.91 ± 0.11 0.95 ± 0.06 <0.0001
Systolic (mmHg) 128.6 ± 17.9 138.7 ± 19.7 <0.0001
Diastolic (mmHg) 78.9 ± 12.2 81.4 ± 11.4 0.0083
FBG (mmol/L) 5.02 ± 0.58 8.91 ± 3.60 <0.0001
HBA1C (DCCT %) 5.47 ± 0.70 7.79 ± 2.09 <0.0001
Insulin (mU/L) 9.72 ± 6.23 20.43 ± 41.87 0.0003
HOMAIR 2.22 ± 1.60 8.03 ± 17.66 <0.0001
Total cholesterol 
(mmol/L)
5.17 ± 1.09 5.13 ± 1.07 0.5694
Triglycerides 
(mmol/L)
1.50 ± 0.87 2.04 ± 1.47 <0.0001
HDL cholesterol 
(mmol/L)
1.14 ± 0.33 1.06 ± 0.28 0.0022
LDL cholesterol 
(mmol/L)
3.40 ± 0.99 3.21 ± 0.94 0.0154
Betatrophin  
(pg/mL)
720.3 (59.5–9345.1) (1710.1 (197.4–
10972.1)
<0.0001
C peptide 606.2 ± 300.1 744.1 ± 419.0 <0.0001
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showed significant positive association in non-dia-
betic subjects between betatrophin and age (r  =  0.50, 
p = < 0.0001), BMI (r = 0.13, p = 0.0018), FBG (r = 0.19, 
p  =  <  0.0001), and insulin (r  =  0.11, p  =  0.00121) as 
shown in Table  2. Strong positive correlation was also 
observed between betatrophin and C-peptide in non-
diabetics subjects (r = 0.28, p = < 0.0001). On the other 
hand, subjects with T2D also showed positive correla-
tion with age (r  =  0.48, p  =  <  0.0001). No association 
was observed between betatrophin and FBG, insulin or 
C-peptide in T2D subjects (Table 2). On the other hand, 
in non-diabetics subjects, C-peptide showed strong posi-
tive association with age (r =  0.17, p =  <  0.0001), BMI 
(r = 0.44, p = < 0.0001), FBG (r = 0.35, p = < 0.0001) and 
insulin (r = 0.72, p = < 0.0001). In T2D subjects, C-pep-
tide showed positive association with BMI (r  =  0.31, 
p  =  <  0.0001) and insulin (r  =  0.35, p  =  <  0.0001) 
(Table 2).
In order to study the effect of betatrophin on C-peptide 
level, our population was divided into tertiles according 
to betatrophin level. Betatrophin was reported as least 
square means adjusted for age, gender and ethnicity as 
shown in Fig. 1. Figure 1 shows a significant increase in 
C-peptide level at higher tertiles of betatrophin in non-
diabetics obese subjects P-trend  =  0.0046. A similar 
trend was also observed in the T2D obese subjects albeit 
not statistically significant P-trend = 0.0983. Non-obese, 
non-diabetics showed a slight increase in C-peptide 
level in higher tertiles of betatrophin P-trend =  0.0691. 
However, the non-obese T2D subject did not show 
any increase in C-peptide level in concordance with 
the increase in betatrophin level as shown in Fig.  1 
(P-trend = 0.9914).
Since betatrophin is strongly correlated with age, 
diabetic and non-diabetic subjects were divided into 
three age groups as follows (<40  years, 40–50  years 
and >50  years old). Level of C-peptide in age-, 
gender- and ethnicity-adjusted least square means ter-
tiles of betatrophin are given in Fig.  2 for the differ-
ent age groups. Figure  2 shows that C-peptide level in 
age group  <40  years is increased in concordance with 
increased betatrophin in the non-diabetics group but not 
the T2D subjects P-trend = 0.0091 and P-trend = 0.6195 
respectively. A similar trend was also observed for the 
other two age groups (40–50  years and  >50  years old) 
where C-peptide was increasing at higher levels of beta-
trophin in non-diabetics subjects only. Taken together, 
our data show that the increased betatrophin level in the 
diabetics is not affecting the C-peptide level across all age 
groups.
Multiple logistic regression analysis of betatrophin and 
C-peptide showed that in the unadjusted model, subjects 
in the highest tertile of betatrophin were more likely to 
have T2D (OR = 16.2, 95 % CI 9.5–27.5) (Table 3). After 
adjustment for age, BMI, gender and ethnicity in Model 
2, subjects in the highest tertile of betatrophin had higher 
odds of having T2D (OR = 7.6, 95 % CI 4.2–13.3). Further 
adjustment for C-peptide in Model 3 moderately attenu-
ated the association, none the less, subjects in the high-
est tertile still had higher odds of having T2D (OR = 7.3, 
95  % CI 4.0–13.3) (P-trend  <  0.0001). Multiple logistic 
regression analysis showed that, in the unadjusted model 
1, subjects in the highest tertile of C-peptide had higher 
odds of having T2D (OR = 2.4, 95 % CI 1.6-3–3.5). After 
adjusting for age, BMI, gender and ethnicity in Model 2 
or model 2 + betatrophin in model 3, no significant OR 
were achieved (Table 3).
Discussion
This study investigated the association between the 
increased betatrophin level in T2D subjects and insu-
lin production as indicated by the C-peptide level. Even 
though, we show strong correlation between the level of 
betatrophin and C-peptide in the non-diabetics group, 
Table 2 Partial Spearman correlations between betatrophin levels and diabetes/metabolic risk factors
Diabetes: fasting plasma glucose ≥7 mmol/L, under treatment, or self‑reported of previously diagnosed T2D; waist/hip ratio. Duration of diabetes was calculated for 
subjects with diabetes. Partial Spearman correlation coefficients were adjusted for age, gender, and ethnicity
BMI body mass index, FBG fasting blood glucose
Variable All T2D Non‑diabetics
Betatrophin C‑peptide Betatrophin C‑peptide Betatrophin C‑peptide
Age 0.56 (<0.0001) 0.17 (<0.0001) 0.48 (<0.0001) −0.02 (0.8049) 0.50 (<0.0001) 0.17 (<0.0001)
BMI 0.17 (<0.0001) 0.41 (<0.0001) 0.13 (0.0535) 0.31 (<0.0001) 0.13 (00.0018) 0.44 (<0.0001)
FBG 0.40 (<0.0001) 0.35 (<0.0001) −0.02 (0.8231) 0.09 (0.1965) 0.19 (<0.0001) 0.35 (<0.0001)
Insulin 0.17 (<0.0001) 0.63 (<0.0001) −0.03 (0.7059) 0.39 (<0.0001) 0.11 (0.0121) 0.72 (<0.0001)
Cpeptide 0.26 (<0.0001) 0.07 (0.3366) 0.28 (<0.0001)
Betatrophin 0.27 (<0.0001) 0.07 (0.3366) 0.28 (<0.0001)
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the T2D subjects did not show any correlation with 
C-peptide. On the other hand, obese subjects showed 
significant increase in C-peptide level at higher levels 
of betatrophin in non-diabetics subjects and a slight 
increase, yet not significant in the T2D subjects. Simi-
larly the non-obese, non-diabetics had a slight increase 
in C-peptide level at higher betatrophin level unlike 
the non-obese T2D which did not show any significant 
increase in C-peptide level at higher levels of betat-
rophin. Increased betatrophin level across different 
age groups caused a significant increase in C-peptide 
level in non-diabetics subjects but not T2D subjects. 
Higher betatrophin levels were associated with 7.3 fold 
increase the odds of having T2D after adjusting for age, 
BMI, gender ethnicity and C-peptide. Taken together, 
our data clearly indicates that increased betatrophin 
level is associated with higher level of c-peptide in 
non-diabetics obese and older subjects but not T2D 
subjects.
Effect of obesity on the association between betatrophin 
and C‑peptide in subjects with or without diabetes
The recent identification of betatrophin role in β-cell 
proliferation in mice has caused an excitement as well 
as confusion in the community about its potential use 
in humans to treat T2D [10, 11, 19, 22, 38–40]. Our data 
as well as others showed that betatrophin is increased in 
T2D subjects [16, 30] as well as T1D subjects [36]. Ani-
mal studies have questioned the ability of betatrophin 
to induce β-cell proliferation in mice [22, 38]. To assess 
whether betatrophin had an impact on β-cells in humans, 
we used C-peptide as an indicator for endogenous insu-
lin production. C-peptide is a cleavage protein released 
during insulin production from its precursor proinsulin 
[32, 41–45]. C-peptide is used clinically to assess β-cell 
function since it reflects the insulin production capabili-
ties of the β-cells [32]. It also has a higher half life and 
very minimal liver clearance compared to insulin and 
reflects the endogenous insulin level in patients treated 
Fig. 1 C‑peptide level according to betatrophin tertiles in non‑diabetics and T2D subjects. a Level of C‑peptide in non‑obese (BMI < 30) non‑
diabetics and T2D subjects at different betatrophin tertiles (betatrophin tertile values for the non‑obese group are T1: ≤1162.5 pg/mL, T2: 
1162.5 ≤ 1881.9 pg/mL, T3: > 1881.9 pg/mL). b C‑peptide level in obese (BMI ≥ 30) non‑diabetics and T2D subjects at different betatrophin tertiles 
(betatrophin tertile values for the obese group are T1: ≤1273.4 pg/mL, T2: 1273.4 ≤ 1881.9 pg/mL, T3: > 1881.9 pg/mL)
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with insulin [32, 43, 45]. Our data clearly showed strong 
correlation between betatrophin and C-peptide in non-
diabetics subjects. Obese subjects had a higher level of 
betatrophin and showed more increase in C-peptide level 
at increasing levels of betatrophin. This increase can be 
due to the state of insulin resistance in obese subjects 
caused by the chronic-low grade inflammation [46–48]. 
Even though β-cells replicate at a very low rate under 
Fig. 2 C‑peptide level for different age groups at different betatrophin tertiles. a C‑peptide level in subjects less than 40 years old stratified accord‑
ing to betatrophin level in non‑diabetics and T2D subjects (betatrophin tertile values are T1: ≤567.6 pg/mL, T2: 567.6 ≤ 763.5 pg/mL, T3: >763.5 pg/
mL). b C‑peptide level in subjects that are between 40 and 50 years old according to betatrophin tertiles in non‑diabetics and T2D subjects (beta‑
trophin tertile values are T1: ≤743.2 pg/mL, T2: 743.2 ≤ 1070.7 pg/mL, T3: >1070.7 pg/mL). c C‑peptide level in subject that are older than 50 years 
old according to betatrophin tertiles in non‑diabetics and T2D subjects (betatrophin tertile values are T1: ≤957.7 pg/mL, T2: 957.7 ≤ 1406.3 pg/mL, 
T3: >1406.3 pg/mL)
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normal condition, a state of insulin resistance can cause 
an increase in β-cell replication [4–6, 8]. Yi et  al. ruled 
out the possibility that betatrophin was inducing insu-
lin resistance to increase β-cell proliferation [11]. Using 
insulin tolerance test they did not observe any difference 
between betatrophin and control injected mice unlike 
the state of insulin resistance they observed in insulin 
receptor antagonist S961 treated mice [11]. As a result, 
it is possible that this increased state of insulin resistance 
is driving the increased betatrophin expression which in 
turn increases the production of insulin.
Effect of age on the association between betatrophin 
and C‑peptide in subjects with or without diabetes
Our work and that of others has shown that betatro-
phin level increases in older subjects [36]. It has been 
speculated that the increase in betatrophin level in older 
subjects is a mechanism for increasing insulin produc-
tion since aging is associated with decreased insulin 
action. Age related factors have been suggested as the 
cause for the age related increased insulin resistance [49, 
50]. These factors include age related changes such as 
decreased lean muscle mass, mitochondrial dysfunction, 
hormonal changes as well as increased oxidative stress 
and inflammation amongst many other changes [49]. The 
increased betatrophin level in older subjects can be a cel-
lular mechanism to compensate for the increased insu-
lin resistance in the non-diabetic subjects. Nonetheless, 
the large increase in betatrophin in T2D subjects was 
not able to affect C-peptide level and insulin secretion. 
In T2D subjects β-cells produce less insulin in response 
to stimuli compared with a normal cell, insulin response 
in stimulated β-cells from T2D subjects can be as low as 
15 % of the normal [8].
It is possible that betatrophin acts as part of a mecha-
nism to compensate for the increased insulin demand in 
insulin resistant subjects as we can see by the increased 
correlation with C-peptide in obese subjects compared 
to non-obese. However, betatrophin alone is not capa-
ble of compensating for this increase in insulin demand 
due to the development of a state of betatrophin resist-
ance or other unknown factors that deem the β-cells 
unresponsive to the increased betatrophin level [30]. This 
was clearly demonstrated in our recent data that showed 
clear lack of association between betatrophin and FBG in 
T2D subjects [30]. Its effectiveness as an inducer of beta-
cells has been also questioned as mentioned earlier by a 
number of reports that emphasises more its role in lipid 
metabolism [18]. On the other hand, this inability of the 
increased betatrophin in T2D subjects to compensate for 
the increased insulin resistance in older T2D subjects 
further supports the notion that beta-cell dysfunction 
is the main cause of T2D pathophysiology and not the 
age related factors mentioned earlier [49]. Overall, these 
findings uncover an important aspect about betatrophin 
and its future use as a β-cell stimulator to treat diabetes.
Conclusion
In conclusion, our data shows strong correlation between 
betatrophin and C-peptide in non-diabetics but not T2D 
subjects suggesting that the increased production of 
betatrophin in T2D is not causing any increase in insulin 
production. In non-diabetics, increased betatrophin level 
is associated with increased C-peptide level highlighting 
the possibility that this increase in betatrophin is driven 
by insulin resistance to compensate for the increased 
insulin demand in obese subjects. Taken together, our 
data show that the increased betatrophin level in T2D 
subjects is not correlating with insulin production and 
its use as a diabetes treatment is questionable. However, 
it remains to be discovered whether betatrophin can be 
beneficial in modulating insulin production in insulin 
resistant non-diabetics obese subjects.
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